Oxford Biomedica plc (LON:OXB)
London · Delayed Price · Currency is GBP · Price in GBX 444.00
+1.00 (0.23%)
Aug 13, 2025, 4:35 PM BST
Oxford Biomedica Revenue
In the year 2024, Oxford Biomedica had annual revenue of 128.80M GBP with 43.84% growth. Oxford Biomedica had revenue of 77.99M in the half year ending December 31, 2024, with 2.67% growth.
Revenue
128.80M
Revenue Growth
+43.84%
P/S Ratio
3.65
Revenue / Employee
151.53K
Employees
850
Market Cap
470.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 128.80M | 39.26M | 43.84% |
| Dec 31, 2023 | 89.54M | -50.45M | -36.04% |
| Dec 31, 2022 | 139.99M | -2.81M | -1.97% |
| Dec 31, 2021 | 142.80M | 55.07M | 62.77% |
| Dec 31, 2020 | 87.73M | 23.67M | 36.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| ConvaTec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| Oxford Nanopore Technologies | 183.19M |
| HUTCHMED (China) | 439.54M |
Oxford Biomedica News
- 16 days ago - UK's Oxford Biomedica maintains annual outlook - Reuters
- 7 weeks ago - OXB completes acquisition of remaining stake in US subsidiary - GlobeNewsWire
- 4 months ago - Oxford Biomedica plc 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 4 months ago - Oxford Biomedica plc (OXBDF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Oxford Biomedica reports FY results; reaffirms medium-term guidance - Seeking Alpha
- 6 months ago - UK Stock Market News: Anglo American, Mony Group, Oxford Biomedica - The Armchair Trader
- 9 months ago - Small Cap Stocks: Oxford Biomedica, Mirriad, United Oil & Gas - The Armchair Trader
- 11 months ago - Half Year 2024 Oxford Biomedica PLC Earnings Call Transcript - GuruFocus